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In the last years, the development of new drugs in oncology has evolved notably. In
particular, drug development has shifted from empirical screening of active cytotoxic
compounds to molecularly targeted drugs blocking specific biologic pathways that drive
cancer progression and metastasis. Using a rational design approach, our group has
developed 1A-116 as a promising Rac1 inhibitor, with antitumoral and antimetastatic
effects in several types of cancer. Rac1 is over activated in a wide range of tumor
types and and it is one of the most studied proteins of the Rho GTPase family. Its
role in actin cytoskeleton reorganization has effects on endocytosis, vesicular trafficking,
cell cycle progression and cellular migration. In this context, the regulatory activity of
Rac1 affects several key processes in the course of the cancer including invasion
and metastasis. The purpose of this preclinical study was to focus on the mode of
action of 1A-116, conducting an interdisciplinary approach with in silico bioinformatics
tools and in vitro assays. Here, we demonstrate that the tryptophan 56 residue is
necessary for the inhibitory effects of 1A-116 since this compound interferes with
protein-protein interactions (PPI) of Rac1GTPase involving several GEF activators. 1A-
116 is also able to inhibit the oncogenic Rac1P29S mutant protein, one of the oncogenic
drivers found in sun-exposed melanoma. It also inhibits numerous Rac1-regulated
cellular processes such as membrane ruffling and lamellipodia formation. These results
deepen our knowledge of 1A-116 inhibition of Rac1 and its biological impact on cancer
progression. They also represent a good example of how in silico analyses represent a
valuable approach for drug development.
Keywords: small-molecule, docking, inhibitor, GTPases, cancer
INTRODUCTION
Rho GTPases are molecular switches that cycle between two conformational states: an inactive
GDP-bound form and an active GTP-bound form. This cycle is highly regulated by guanine
nucleotide exchange factors (GEFs), which catalyze nucleotide exchange and mediate Rho GTPase
activation, and GTPase-activating proteins (GAPs), which stimulate GTP hydrolysis to return the
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GTPases to the inactive, GDP-bound state. The active, GTP-
bound Rho proteins bind preferentially to downstream effector
proteins to engage the downstream biological responses (Jaffe
and Hall, 2005; Bustelo et al., 2007; Bustelo, 2018). Additionally,
Rho GTPases are regulated by a wide range of post-translational
modifications, such as prenylation, proteolytic cleavage,
methylation, phosphorylation, sumoylation, and ubiquitination,
to ensure specific spatiotemporal activation (Bustelo et al., 2007;
Rathinam et al., 2011).
Rho GTPases are readily activated by different stimuli that
activate a wide variety of cell-surface receptors, including
receptor tyrosine kinases (RTKs), G-protein-coupled receptors
(GPCRs), cytokine receptors, integrins and cadherins (Bustelo,
2018). These stimulated receptors ultimately promote the
exchange of GDP for GTP on Rho proteins, mainly by GEF
activation. To date, more than 70 GEFs have been reported. Some
of the most well described GEFs include Tiam1, Dbl, Vav family,
P-Rex1, Dock-180 (Vigil et al., 2010).
Rac1 is one of the most studied members of Rho-GTPases
family and controls fundamental cellular processes. Rac1 is
a significant regulator in actin cytoskeleton reorganization,
affecting endocytosis trafficking, cell cycle progression, cell
adhesion, and migration (Etienne-Manneville and Hall, 2002;
Bustelo et al., 2007). Accumulating evidence indicates that Rac1
is overexpressed and hyperactivated in a wide range of tumors
and its influence on cytoskeleton remodeling affects key processes
such as invasion, migration, and metastasis of cancer cells (Sahai
and Marshall, 2002; Bustelo, 2018). Other GTPases, such as
RhoA, RhoG, and Ccd42, have also been associated with cancer
progression (Bustelo, 2018).
We have previously reported the rational design and
development of the novel Rac1 inhibitor 1A-116. This compound
was identified using a structure-based drug discovery approach
(SBDD) that involves virtual library screening and docking using
tryptophan 56 (W56) as a target of Rac1 3D structure. This amino
acid is a crucial residue for Rac1 activation by different GEFs
(Gao et al., 2001). Importantly, W56 residue is not unique to
Rac1 protein. In fact, it is highly conserved in other members
of the Rho GTPase family of proteins, such as Rac2/3 and
RhoA/B/C/D/G (Haeusler et al., 2003). 1A-116 Rac1 inhibitor
showed antitumoral activity in vitro on a wide variety of cancer
types such as breast cancer (Cardama et al., 2014a; Gonzalez et al.,
2017), glioblastoma (Cardama et al., 2014b) and acute myeloid
leukemia (Cabrera et al., 2017). In this regard, we have already
reported that 1A-116 has a profound effect on proliferation,
migration, invasion, metastasis, apoptosis, and cell cycle arrest.
Protein flexibility is a fundamental requirement for most
biological functions. Indeed, the use of a single protein structure
in SBDD implies accepting the outdated lock-and-key model as
the unique recognition process between protein and ligands. In
contrast, considering the conformational diversity of a protein
may improve the probability succeeding in discovering novel
active compounds (Setiawan et al., 2018).
In this work, we show evidence of the mechanism of
action involved in 1A-116 biological activity. Our results
support the relevance reported of W56 residue for 1A-116
activity, confirming the previous SBDD approach used for its
identification. We also carried out a detailed analysis of the
conformational diversity of Rac1, considering all the available
crystallographic structures in the Protein Data Bank (PDB).
Using docking experiments, we analyzed the stability of Rac1-
1A116 interactions. In addition, we evaluated the ability of 1A-
116 to interfere with Rac1 protein-protein interactions (PPI) with
a broad spectrum of GEFs involved in the tumoral phenotype. In
particular, we showed that 1A-116 inhibits the interaction of Rac1
with Vav1, Vav2, Vav3, Tiam1, and Dbl. Finally, we showed for the
first time that 1A-116 inhibits Rac1P29S, a rapid-cycling mutant of
Rac1 that is frequently found in melanoma and other tumor types
(Bustelo, 2018). We also demonstrate that 1A-116 prevented




COS-1 cells (ATCC R© CRL-1650TM) from African green
monkey kidney fibroblast-like cell line were obtained from
the American Type Culture Collection (ATCC). Cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
(Life Technologies) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 2 mM glutamine and 80 µg/ml
gentamicin at 37◦C in 5% CO2 atmosphere. Cell cultures
were routinely subcultured twice a week by trypsinization and
EDTA treatment (Gibco, Rockville, MD, United States), using
standard procedures.
Drugs
Chemo Argentina/Romikin S.A. kindly provided Rac1 inhibitor
1A-116 (Cardama et al., 2014a). The compound was synthesized
under GMP conditions. Purity (HPLC): >99.3% 1A-116
was solubilized in aqueous solution at pH 5.5, by the
addition of HCl 100 mM.
Computational Conformational Analysis
of Rac1 and Docking Experiments
The human Ras-related C3 botulinum toxin substrate 1 (Rac1)
crystal structures were retrieved from the Protein Data Bank
(PDB) (Berman et al., 2000). A total number of fifty-two (52)
conformations, excluding structural mutants, were used for the
analysis. The only single-point mutant conformations considered
for the analysis were: the constitutively active mutant Q61L;
the self-activating mutants P29S and F28L; and the dominant
negative mutant T17N. A list of all the conformations used,
together with a brief summary of their features, can be found in
Supplementary Table 1. Root-mean-square deviation (RMSD)
between all conformers and the Z-Scores derived from each
C-alpha RMSD were calculated using a database of protein
conformational diversity (CoDNaS) developed by Monzon et al.,
2016. The 3D structure predictions of Rac1 W56F and CDC42
F56W single-point mutants were carried out by the I-TASSER
server (Yang et al., 2015). The crystal structure of wild type Rac1
and CDC42 (1MH1 and 2QRZ) were obtained from the PDB and
used as templates.
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For the docking experiments, the pockets containing the
residue W56 of Rac1 and F56 of Cdc42 were used as targets.
The docking was centered on the C-alpha of this residue with a
grid size of 14 1Å. AutoDock Vina was used as docking software
(Trott and Olson, 2010). Each docking experiment was repeated
one hundred times to determine the mean docking energy± SD.
Cell Proliferation Assays
COS-1 cells were plated in 96-wells plates and 24 h later
were treated for 24 h with different concentrations of 1A-
116. Cell growth was measured by colorimetric MTT assay
(Sigma). The concentration producing 50% inhibition (IC50)
was determined by non-linear regression function PRISM 6,
Version 6.01 (GraphPad Prism6 R© Software Inc., La Jolla, CA,
United States). Results shown correspond to the average of three
independent experiments.
Serum-Response Assays
4 × 105 COS-1 cells per well were plated into 6-well plates.
Plasmids were diluted in OptiMEM (ThermoFisher Scientific),
the transfection reagent Lipofectamine LTX (GIBCO/BRL,
Gaithersburg, Maryland) was added to the DNA solution
and incubated for 25 min at room temperature. Next, the
DNA-Lipofectamine complexes were added to the cells and
incubated overnight. Subsequently, the cells (in triplicate) were
treated with vehicle (H2O) or 1A-116 50 µM for 24 h.
Cells were then harvested and cell lysates were assayed for
luciferase activity (Renilla normalized) utilizing the Dual-
Luciferase Reporter Assay System (Promega) following the
manufacturer’s instructions. The plasmids used for the GEFs
experiments were: pCEFL-AU5, empty vector; pNM108, plasmid
encoding the constitutively active version of Vav1 (Vav1 11-
189); pNM115, plasmid encoding the constitutively active
version of Vav2 (Vav2 11-186); pNM099, plasmid encoding
the constitutively active version of Vav3 (Vav3 DH-PH-ZF);
pcDNA.3-HA-C1199, plasmid encoding the constitutively active
version of Tiam1 [Tiam1 C1199 (aa 391-1590)]; DBL-onco,
plasmid encoding the constitutively active version of DBL
(oncogenic Dbl, through truncation of the N-terminal 497
residues). For the GTPases experiments, the plasmids used were:
pCEFL-AU5, empty vector; pCEFL-AU5-Rac1 Q61L, plasmid
encoding the constitutively active version of Rac1; pJRC27,
plasmid encoding the constitutively active version of Cdc42.
Lastly, the plasmids used for specificity of 1A-116 were pNG01
and pNG02, encoding the Rac1 W56F Q61L and Cdc42 F56W
Q61L mutants, and the Rac1 P29S mutants generated by site-
directed mutagenesis procedures described below.
Site-Directed Mutagenesis
Site-directed mutagenesis was carried out using the QuikChange
kit according to the manufacturer’s instructions. To generate the
vector encoding AU5-Rac1 W56F Q61L (pNG01), we used the
pCEFL-AU5-Rac1 W56F (pJRC27) plasmid as template and the
oligonucleotides 5′-GAT ACA GCT GGA CTA GAA GAT TAT
GAC-3′ (forward) and 5′-GTC ATA ATC TTC TAG TCC AGC
TGT ATC-3′ (reverse). To generate the vector encoding AU5-
Cdc42 F56W Q61L (pNG02), we used the plasmid pCEFL-AU5-
Cdc42 Q61L (pJRC27) as template and the oligonucleotides 5′-
CTC TTG GAC TTT GGG ATA CTG CAG G-3′ (forward) and
5′-CCT GCA GTA TCC CAA AGT CCA AGA G-3′ (reverse).
To generate the Rac1 P29S mutants, we used the pCEFL-AU5-
RAC1 WT plasmid as template (for the Rac1 wt P29S) and the
pCEFL-AU5-RAC1 Q61L (for the Rac1 P29S Q61L) and the
oligonucleotides 5′-AGT TAC ACA ACC AAT GCA TTT TCT
GGA GAA TAT ATC CCT ACT GTC-3′ (forward) and 5′-GAC
AGT AGG GAT ATA TTC TCC AGA AAA TGA TTG GTT GTG
TAA CT-3′ (reverse). Oligonucleotides were purchased from
Thermo Fisher Scientific. All plasmids were sequence-verified at
the Genomics and Proteomics Facility of Centro de Investigación
del Cáncer, Salamanca, Spain.
Rac1 Pull Down Assay
COS-1 cells were plated in p100 dishes. Next day, cells were
transfected with pCEFL-AU5 or pCEFL-AU5-Rac1 Q61L, using
CaCl2 and 24 h later monolayers were treated or not with 1A-
116 50 µM for another 24 h period. Monolayers were washed
with PBS and lysed in 150-GPLB Buffer supplemented with
a protease inhibitor cocktail. Lysates were clarified and the
protein concentrations were normalized. An aliquot was removed
for determination of total Rac1 and the rest was incubated
with Glutathione Sepharose 4B Beads, coupled with bacterially
expressed GST-PAK1. Bound complexes were washed with lysis
buffer, resuspended in protein sample buffer, boiled and loaded
onto a 12% SDS-PAGE gel. Proteins were transferred and blotted
with mouse monoclonal antibody against Rac1 (Sigma). SDS-
PAGE and Coomassie Blue staining was used to check the
integrity of the purified GST-PAK1 fusion proteins.
3D Organotypic Cultures
2 × 105 human keratinocytes Ker-CT cells were seeded onto
polycarbonate inserts (ThermoFisher, Catalog No. 140620) and
cultured for 2 days in CnT–Prime medium. When confluency was
reached, medium was changed to 3D–Barrier (CellnTec, Catalog
No. CnT–PR–3D) and the air–lift was performed according to
the manufacturer’s instructions. 3D cultures were maintained
for 11 days with three medium changes per week. Treatment
with 1A-116 (100 nM) was performed on the sixth day post
air-lift. 1A-116 concentration was selected based on the minor
effect induced in the organotypic structures formed by control
cells. Immunohistochemistry studies were performed in the
Pathology Service of the Cancer Research Center (Salamanca,
Spain), fixing the 3D cultures for 16 h at 4◦C, filling the well
and the interior of the insert with paraformaldehyde at 3.7%.
The skin/membrane structure was cut and proceeded to inclusion




COS-1 cells were grown on 6-well plates and transfected
with the constitutively active Rac1 Q61L plasmid, tagged at
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its N-terminus with EGFP (pNM42) or the empty vector
pEGFP-C1 (as control), using Lipofectamine 2000 (GIBCO/BRL,
Gaithersburg, Maryland). To that end, we mixed 1 µg of
plasmid and 3 µl of Lipofectamine in 100 µl of serum-
free OptiMEM. The transfection mix was then added into
each well, cells cultured for 24 h and trypsinized. We then
seeded them onto polylysine-coated coverslips and treated
cells with vehicle or 1A-116 50 µM for an additional 24 h.
Upon culturing under indicated experimental conditions, cells
were fixed with 3.7% paraformaldehyde and subjected to
conventional immunofluorescence techniques. In brief, cells were
permeabilized with Triton X-100 0.5% m/v in TBS [25 mM Tris-
HCl (pH 8.0), 150 mM NaCl] during 10 min of gentle agitation.
Permeabilization buffer was removed and cells were washed with
TBS (3 times, for 5 min) and then coverslips were blocked for
10 min with blocking solution (2% bovine serum albumin (BSA),
0.1% m/v sodium azide, 0.1% m/v Tritón X-100, 25 mM Tris
(pH 7.5, adjusted by the addition of HCl 1M) (2% m/v BSA
TBS), on gentle agitation. To visualize the F-actin cytoskeleton,
cells were subsequently incubated with Alexa Fluor 635-labeled
phalloidin diluted 1:200 in blocking solution for 20 min, washed
three times with TBS, and stained with DAPI to visualize nuclei.
The stained preparations were mounted on microscope slides
using Mowiol (Calbiochem). Samples were analyzed by confocal
microscopy using a Leica SP5 confocal microscope with a 63x-
objective (Leica).
Statistical Analysis
Statistical analyses were carried out using PRISM 6 software,
Version 6.01 (GraphPad Prism6 R© Software Inc., La Jolla,
CA, United States). Results of this work were expressed as
mean ± SEM; mean ± SD; mean ± confidence interval (CI).
For multi-group analyses, one- or two-way ANOVA was applied,
followed by Tukey’s multiple posterior comparisons test, or 95%
CI comparison, as appropriate. The normal distribution of the
data was determined using the D’Agostino-Pearson normality
test. In addition, homoscedasticity was evaluated with the Bartlett
test. For the data that did not follow a normal distribution or
when the homoscedasticity was not met, the Kruskal–Wallis
test was performed. In all cases, the differences were considered
statistically significant at p < 0.05.
RESULTS
Drug-Like Properties of 1A-116
1A-116 (Figure 1A) is a small compound previously described
by our group that was developed by a rational design approach
using in silico virtual screening. In previous reports, we showed
that 1A-116 was able to inhibit Rac1-GEF interactions reducing
Rac1 activation levels and showing anti-proliferative effects on
different cancer cell lines (Figure 1B; Cardama et al., 2014a,b;
Cabrera et al., 2017; Gonzalez et al., 2017) but not in COS-1 cells
used in the luciferase assays (Figure 1C). The drug-likeness of
this small molecule compound meets Lipinski’s rules for small
molecule drugs (Lipinski et al., 2001; Lipinski, 2004). As shown
in Figure 1D, 1A-116 has a molecular weight of 307.32 g mol−1
with a predicted logP of 4.67. Moreover, it has two hydrogen bond
donors and three hydrogen bond acceptors. In concordance with
Veber’s rules (Veber et al., 2002), 1A-116 also meets the criteria of
a small-molecule-drug-like compound with three rotatable bonds
and a molecular polar surface area of 50.41 Å2, which is below
the 140 Å2 recommended by Veber. These key physicochemical
properties showed good drug-likeness and suggested good oral
availability for this compound.
In silico Conformational Diversity
Analysis of Rac1 Crystallographic
Structures
1A-116 family of small compounds was identified using an SBDD
strategy, which involves the use of a single protein structure
(PDB ID code 1MH1). Lately, it has been recognized that the
conformational diversity of a protein is central to understanding
protein function. This conformational diversity implies that
proteins are not structured in a unique conformation and present
differences between these conformations, having a potential
impact on the success of the drug-target binding.
To further characterize the protein functionality of Rac1 and
to take into account the conformational diversity of the Rac1
structure, all the crystal structures (fifty conformers without
mutations) of Rac1 available in the PDB were retrieved.
By evaluating the RMSD scores, we could identify the pair of
conformers of Rac1 that exhibited the maximal conformational
diversity (1E96A vs. 2YINC, RMSD 2.5 Å). We also calculated
the Z-Scores derived from Carbon-alpha RMSD per position
of the maximum-pair of conformers, focusing on the binding
site. We first surveyed the W56 residue and then in N52, S41,
N39, and K5 residues since they are also involved in Rac1-1A116
interaction. The Z-Score distribution revealed reduced relative
mobility of the residues involved in the interaction with 1A-116
(Figure 2A). These results indicate that W56 and the residues in
close contact with 1A-116 are located in a relatively low mobility
region within the Rac1 structure, contributing to the idea that
W56 is an appropriate residue to target with small molecules to
interfere Rac1-GEF interaction.
We further performed an exhaustive re-docking analysis to
assess the interaction of 1A-116 with all the available X-ray
structures of Rac1 deposited in the PDB. Autodock Vina was used
to calculate the interaction of 1A-116 with all Rac1 conformers.
The results showed that 1A-116 is predicted to bind with
high affinity, with a mean affinity of −6.02 ± 0.315 kcal/mol
(Figure 2B), suggesting that 1A-116 binds stably to all the
reported conformational states of Rac1.
Furthermore, we calculated the RMSD scores between the
best-docked positions of 1A-116 to the maximum pair of Rac1
structures to evaluate the binding mode of 1A-116. As shown in
Figure 2C, 1A-116 interacts with both conformers through the
same residues. The H-Bond with W56, which is crucial for the
interaction, is present in both conformers. We also analyzed the
position of 1A-116 with each Rac1 conformer and obtained an
RMSD score of 4.24 Å, with a similar affinity in both cases (-
5.867 ± 0.1803 kcal/mol to 1E96A, −6.122 ± 0.2539 kcal/mol
to 2YINC) (Figure 2D). While the 2-trifluoromethylphenyl
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FIGURE 1 | 1A-116 is a Rac1 inhibitor. (A) Chemical structure of 1A-116. (B) Antiproliferative effects of 1A-116 1A-116 in different cancer cell lines. (C) Effects of
1A-116 in COS-1 cells used in SRE-activation assays. (D) Drug-like and physicochemical properties of 1A-116.
group (ring A) has an RMSD score of 5.51 Å, both the 3,5-
dimethylphenyl group (ring B) and the guanidine are docked
in a more similar position, with an RMSD score of 1.35 Å and
1.47 Å. This finding shows that the ring B and guanidine, which
provides the H-Bond between 1A-116 and Rac1, are docked
similarly in the maximum RMSD pair. In addition, the rotatable
bonds near to ring A allows 1A-116 to adopt a stable position in
both conformers.
Tryptophan 56 of Rac1 Is Required for
the Inhibitory Effects of 1A-116
Rac1 and Cdc42 share approximately 70% sequence homology,
although they differ in specific key residues (Figure 3A).
For example, the tryptophan residue of position 56 (W56)
of Rac1 is substituted by a phenylalanine (F56) residue in
the case of Cdc42 (shaded area in gray). As we mentioned
above, the W56 residue has been established as the central
target for the identification of 1A-116 as Rac1 inhibitor
(Gao et al., 2001).
To further evaluate the critical role of W56 in the Rac1-1A-
116 interaction, several docking experiments were performed
using Rac1 (1MH1A) and CDC42 (2QRZB) PDB structures
as receptors. Additionally, we also carried out in silico
experiments using single-point mutants, replacing W56 in Rac1
for phenylalanine residue and replacing the F56 residue of Cdc42
for a tryptophan. Rac1 W56F and CDC42 F56W 3D models
were generated with the I-TASSER software (Figures 3B,C). As
seen in Figure 3D, when 1A-116 is docked to Rac1 W56F, the
compound affinity for the GTPase decreases, showing a docking
energy of −6.08 ± 0.226 kcal/mol (vs. −5.59 ± 0.0139 kcal/mol
of the wild-type Rac1). Furthermore, when the affinity of 1A-
116 for Cdc42 and Cdc42 F56W was evaluated, a clear increase
of its binding affinity is observed (from -5.69 ± 0.0170 to -
6.09 ± 0.00994 kcal/mol, respectively. The absence of W56 in
Rac1 structure or mutant Cdc42 causes the loss of the H-bond
between 1A-116 and the protein as shown in Figures 3B,C. In
summary, we validated the relevance of the H-bond established
between 1A-116 and W56 of Rac1 for this drug-protein
interaction in silico.
We then evaluated the specificity of 1A-116 for the W56
site in vitro. For this purpose, we carried out site-directed
mutagenesis to generate the two mutant versions of Rac1 and
Cdc42 to recapitulate the in silico experiments. We used the
SRE-Luc reporter system, containing the serum response element
(SRE) fused to the luciferase gene to evaluate the effects of these
mutations in 1A-116 biological activity. At day zero, COS-1 cells
were co-transfected with Rac1 and Cdc42 plasmids (and carried
out an SRE-Luc activation assay in the presence or absence of
1A-116 for 24 h, together with the reporter plasmids SRE-Luc
and Renilla. As negative control, we used cells transfected with
the empty expression vector (EV). As shown in Figure 3E, 1A-
116 inhibits SRE-activation mediated by Rac1 by 40%. However,
this inhibition is lost in the case of the W56F mutant version of
Rac1. We also observed that 1A-116 could not inhibit the Cdc42-
mediated activation of SRE. However, it does so in the case of cells
expressing the Cdc42 F56W mutant. (Figure 3E). These findings
support the idea that the W56 residue of Rac1 is necessary for the
inhibitory activity of 1A-116.
Finally, we studied the effect of 1A-116 in a rapid nucleotide
cycling mutant of Rac1 that bears the P29S mutation (Figure 3A,
shaded area). We first evaluated the interaction of 1A-116 with
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FIGURE 2 | In silico Conformational diversity analysis of Rac1 crystallographic structures. (A) RMSD as Z-score for each pair of residues aligned in the maximum
pair of conformers. Residues with a Z-Score lower than zero show a lower average mobility and therefore higher stability. Red dots represent the residues in close
contact with 1A-116. (B) Distribution of binding affinities of 1A-116 against all the conformers of Rac1 by redocking experiments. In the X-axis the binding affinity in
kcal/mol were plotted and in the Y-axis the relative frequency expressed in percentage of each binding affinity value (Mean -6.02 ± 0.315 kcal/mol) were plotted.
(C) 1A-116 docked against the maximum RMSD pair of Rac1 conformers (1E96A gray, 2YINC white). The guanidine of 1A-116 establishes a H-Bond with Rac1 in
both conformers. While the B ring is docked in the same position, the A ring is slightly rotated. (D) Binding affinity of 1A-116 against maximum pair of conformers
obtained by redocking experiments.
this mutant using an in silico docking strategy with the crystal
structure of this mutant protein (3SBDA PDB structure). We
found that the predicted affinity of 1A-116 for this mutant
is similar to that calculated with the Rac1 wild-type structure
(1MH1A) (-6.18 ± 0.0402 kcal/mol) (Figure 3D). To study
the effect of 1A-116 on this mutant in vitro, we generated a
double Rac1 mutant harboring both the P29S and the Q61L
substitutions and test its activity on SRE experiments in the
presence and absence of the inhibitor. As shown in Figure 3E, 1A-
116 is also able to inhibit SRE-activation mediated by both P29S
mutants, indicating that 1A-116 can inhibit the gain-of-function
mutation of Rac1. Figure 3F shows western blot expression
detection of transfected exogenous proteins.
1A-116 Inhibits the SRE-Activation
Mediated by Different GEFs
To identify which interactions between Rac1 and different GEFs
were inhibited by 1A-116, we evaluated the effect of the 1A-
116 inhibitor in the SRE activity elicited by a number of
activated versions of Rac1 GEFs when ectopically expressed
in COS1 cells. Those activated GEFs included Vav1 11-189,
Vav2 11-186, Vav3 DH-PH-ZF, Tiam1 C1199 (aa 391-1590)
and oncogenic Dbl (through truncation of the N-terminal 497
residues). We found that 1A-116 also inhibits the activation of
all those GEFs, with percentages of inhibition of 40-50% (Vav
family GEFs), 60% (Dbl) and 75% (Tiam1) (Figure 4A). Figures
4B–D show western blot expression detection of transfected
exogenous proteins.
1A-116 Inhibits Rac1 Activity at the
GEF-Rac1 Level
In order to shed light on the hypothesis that 1A-116 inhibits
Rac1 activity at the GEFs-Rac1 interaction level, we carried
out a 3D differentiation assay using a human keratinocytes
cell line and different pull-down assays, using two different
experimental schemes.
First, we used stably transfected Ker-CT human keratinocytes
cell lines with active versions of different components of the
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FIGURE 3 | The W56 amino acid residue of Rac1 is necessary for the inhibitory effects of 1A-116. (A) Alignment of amino acid sequences of Rac1 (Uniprot ID
p63000) and Cdc42 (Uniprot ID p60953). The shaded areas in gray mark the difference in the aminoacid 56, a key residue in Rac1-activation mediated by different
GEFs and the Rac1 P29S mutation. (B) 2D representations of 1A-116 interaction with Rac1 WT and mutants (W56F and P29S). (C) 2D representations of 1A-116
interaction with Cdc42 WT and F56W mutant. (D) Predicted affinity (kcal/mol) of 1A-116 for different Rac1 and Cdc42 structures using AutoDock Vina software.
Each docking experiment was repeated one hundred times to determine the mean docking energy ± SD. ANOVA; ns, not statistically significant; ****p < 0.0001.
(E) COS-1 cells were co-transfected with active versions of Rac1 (Q61L), Cdc42 (Q61L), and the mutants versions of Rac1 (W56F Q61L, P29S, and P29S Q61L)
and Cdc42 (F56W Q61L), together with the SRE-Luc and Renilla reporter plasmids. Cells were treated (+1A-116, white) or not (-1A-116, black) with 1A-116 50 µM
and luciferase activity was measured. (F) Western blot expression detection of transfected exogenous proteins. The expressed protein is reported and the primary
antibodies used (WB) were: α-AU5 for EV, Rac1 Q61L, Cdc42 Q61L, Rac1 W56F Q61L, Cdc42 F56W Q61L, Rac1 P29S, Rac1 P29S Q61L and α-Tubulin as a
loading control. Error bars, SEM t test; ns, not statistically significant; *p < 0.05; **p < 0.01; ***p < 0.001; vehicle vs. 1A-116 for each protein. Luciferase expression
was relativized to Renilla expression value (transfection control) and values reported are shown as an increase in activity with respect to the mean luciferase
expression of the empty vector (EV), in arbitrary units (a.u.). Results are representative of at least three independent experiments.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 7 April 2020 | Volume 8 | Article 240
fcell-08-00240 April 9, 2020 Time: 18:22 # 8
González et al. Pharmacodynamics of 1A116 Rac1 Inhibitor
FIGURE 4 | 1A-116 inhibits SRE-activation mediated by different GEFs. (A) COS-1 cells were co-transfected with active versions of different GEFs together with
SRE-Luc and Renilla reporter plasmids, treated (+1A-116, white) or not (-1A-116, black) with 1A-116 50 µM and luciferase activity was measured. (B–D) Western
blot expression detection of transfected exogenous proteins. The expressed protein is reported and the primary antibodies used (WB) were: α-EGFP for EV, Vav1
11-189, Vav2 11-186 and Vav3 DH-PH-ZF; α-HA for Tiam1 C1199; α-DBL for oncogenic DBL and α-Tubulin as a loading control. Error bars, SEM t test; ns, not
statistically significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; vehicle vs. 1A-116 for each protein. Luciferase expression was relativized to Renilla
expression value (transfection control) and values reported are shown as an increase in activity with respect to the mean luciferase expression of the empty vector
(EV), in arbitrary units (a.u.). Results are representative of at least three independent experiments.
Rac1 signaling pathway: a GEF-type activator (oncogenic Vav2),
a fast cycling version of Rac1 (Rac1 F28L) and a direct
constitutively active effector of Rac1 (PAK1 Tyrosine 423). The
assay was carried out by culturing the cells on polycarbonate
inserts, treated or not with 1A-116 at concentrations in
the nanomolar range (100 nM). Ker-CT wild type cells
growing under these conditions developed a distinctive stratified
epidermal architecture composed of proliferative basal and
suprabasal differentiated keratinocytes, as well as a superficial
stratum corneum (Figure 5A; wild-type, vehicle panel). This
3D organotypic structure did not suffer anyalteration when
treated with 1A-116 (Figure 5A; wild-type, 1A-116 panel). The
stable overexpression of different active components of the Rac1
signaling pathway caused the development of hyperplasia and the
formation of a disorganized and invasive epithelium (Figure 5A;
Vav2, Rac1, PAK1, vehicle panel). These cells also form thicker
epidermal layers than wild-type cells, under the same conditions
(Figure 5B). However, when treated with 1A-116, this phenotype
was reversed in the case of Vav2 and Rac1-mediated hyperplasia,
decreasing the thickness of the epidermal layers (Figure 5B), but
not in the PAK1-mediated one (Figure 5A, Vav2, Rac1 and PAK1,
1A-116 panel). In the case of pull-down assay, COS-1 cells were
transfected with Rac1 Q61L that were either treated or untreated
with 1A-116 for 24 h. We carried out the pull-down, showing a
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FIGURE 5 | 1A-116 acts by inhibiting Rac1 activity at the GEFs-Rac1 level. (A) Representative histological sections of 3D organotypic cultures of human
keratinocytes expressing the indicated proteins (left), treated or not with 1A-116 100 nM. (B) Quantification of the epidermal thickness area using data from panel A.
t test; ns, not statistically significant; *p < 0.05; ***p < 0.001. (C) Transfected COS-1 cells Rac1 Q61L were treated with vehicle (-) or with 1A-116 50 µM (+). Cell
lysates were precipitated by pull-down assay with GST-PAK1. Densitometric values are reported (arbitrary units taking Rac1 Q61L treated with vehicle as 1). The
western blot analysis was carried out using an anti-Rac1 antibody.
decrease in Rac1-GTP levels by 1A-116 (Figure 5C). This result
indicates that the Rac1-GTP levels have not been altered by the
inhibitor, because the activation by GEFs was not taking place
since we only studied the interaction of 1A-116 with the already
active protein lysate.
Taking the 3D differentiation assay and in vitro pull-down
assay together, these results corroborate the hypothesis that 1A-
116 is acting at GEFs-Rac1 interaction level.
1A-116 Inhibits Rac1-Regulated
Processes, Like Ruffles and Lamellipodia
Formation
Finally, we evaluated the effect of 1A-116 on the rearrangement
of cytoskeleton induced by Rac1, by transfecting COS-1 cells with
Rac1 Q61L version fused at its N-terminal with EGFP. After
24 h, we subcultured and seed the cells in poly-lysine coated
glass and treated them for 16 h with 1A-116. Then, we fixed
and stained cells with AlexaFluor555-phalloidin and DAPI and
analyzed them by confocal microscopy. As shown in Figure 6
(vehicle, upper row), Rac1 Q61L expression generated peripheral
ruffles formation, which co-localize with Rac1. However, this
phenotype was abolished when cells were treated with 1A-116
(Figure 6, 1A-116, bottom row), showing once again that this
compound inhibits cellular processes involved in the metastatic
cascade and regulated by Rac1.
FIGURE 6 | 1A-116 inhibits formation of ruffles and lamellipodia, cellular
processes regulated by Rac1. COS-1 cells transfected with Rac1 Q61L fused
to EGFP (Rac1 Q61L-EGFP) were cultured in poly-lysine coated glasses and
treated with 1A-116 50 µM or not (vehicle) for 24 h. Cells were fixed and
stained with AlexaFluor555-phalloidin and DAPI (to observe the actin filaments
and nuclei, respectively) and were observed by confocal microscopy (63×).
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DISCUSSION
The elucidation of the specific mechanism of action associated
with novel therapeutic compounds is a crucial component of the
drug discovery process. Given the high attrition rates in drug
discovery, it is of great interest having a deep understanding
of drug activities before exploring the clinical benefit of these
molecules. Here, we provide data regarding the pharmacology of
the Rac1 inhibitor, 1A-116, a small molecule developed by our
group that has already shown promising preclinical performance
(Cardama et al., 2014a,b; Cabrera et al., 2017; Gonzalez et al.,
2017). For this purpose, we conducted an interdisciplinary
approach taking advantage of bioinformatics, confirming this
information with in vitro testing and finally, analyzing different
events in cell-based assays where Rac1 plays a vital role.
1A-116 compound is a PPI inhibitor developed by our
group using a rational design approach. Targeting PPIs has
been a neglected strategy for many years; however, it has
become clear that some regions are more critical for protein
binding than others, in the large interfaces spanning these
PPIs. This provides the opportunity to determine which few
residues contribute significantly to the free energy of binding
between interacting proteins and to design small molecules
able to block those residues involved. The 1A-116 compound
was first identified using a docking-based virtual screening
approach (Cardama et al., 2014a), based on the knowledge that
Rac1 possesses a particular area in its structure responsible
for interacting with GEF-type activators (Gao et al., 2001).
Of interest, one particular residue, the tryptophan (W56),
seems to be a significant determinant of this PPI and this
particular residue was placed as the target to conduct the
virtual screening. At that time, a single crystallographic structure
was used in the structure-guided design of this GEF-Rac1
inhibitor. However, this method did not take into account
the possibility of substantial flexibility of the protein structure
and only addressed the selected binding site within the
protein as a static or rigid structure. It has been shown
that protein flexibility is a key component to take into
consideration for drug design (Teague, 2003; Arkin and Wells,
2004). To evaluate how protein flexibility affects Rac1-1A-116
interaction, we took advantage of all the Rac1 crystal structures
available and deposited in the PDB to span the spectrum of
possible conformations. The structural differences between these
conformers characterize the conformational diversity of the
protein (Palopoli et al., 2016) and we hypothesized that these
differences might have a profound impact on protein function
and 1A-116 activity.
Experimentally, the differences between structures can be
determined using the RMSD score distribution of all conformers.
The analysis of Rac1 conformational diversity shows that while
globally Rac1 has a flexible structure (RMSD of maximum
pair = 2.5 Å), the residues engaged by 1A-116 binding, and
specifically the W56, have a Z-Score below zero, showing
relatively low mobility within protein structure. This stable
region of the protein allows 1A-116 to effectively bind to Rac1;
taking into account the flexibility of the protein. Rac1, like
other GTPases, can undergo conformational changes depending
on their union with GTP or GDP. However, our results
analyzing the Z-score per residue taking into account all
the Rac1 conformers available in the PDB show that the
amino acids involved in the interaction with the compound
correspond to a zone of low mobility beyond the nucleotide
to which it is bound. This concept does not contradict the
proposed mechanism of action for the compound, meaning
the interference of the Rac1-GEF interaction. This highlights
W56 and the surrounding residues as an interesting and
stable zone for targeted therapies taking into account the
conformational diversity of Rac1. Furthermore, through the
re-docking analysis of 1A-116 to the maximum RMSD pair
of conformers, we were also able to determine the nature
of the interaction of 1A-116 with Rac1. In this sense,
1A-116-Rac1 interaction is predominantly achieved through
the 3,5-dimethylphenyl group (Ring A) and the H-bond
established by the guanidine with the W56. Moreover, the 2-
trifluoromethylphenyl group rotatable bonds allows 1A-116 to
adopt the most favorable pose to each conformer with no loss of
binding affinity.
In addition, W56 residue resides in a highly conserved
region of the GTPases that belong to the Ras superfamily;
e.g., W56 in Rac1 corresponds to L56 in Ras GTPase. In
fact, L56 in Ras oncoprotein has been described as one of
residues surrounding the binding pocket of Ras small molecule
inhibitors (Maurer et al., 2012; Schöpel et al., 2016) or even
being one of the residues being bound by the inhibitor
(Cruz-Migoni et al., 2019).
It is important to emphasize that solely the ability for a ligand
to bind to a certain binding site, does not make a compound a
suitable inhibitor with therapeutic perspectives: “drug-likeness”
is one key determinant for drug discovery process. In this
regard, 1A-116 meets all the criteria of drug-likeness stated by
Lipinsky and Veber (Lipinski et al., 2001; Veber et al., 2002;
Lipinski, 2004) as shown here, making it possible to formulate
an oral vehicle for it.
Even though the initial virtual screening was designed to
identify W56-interacting small molecules, we show here the
critical role of W56 in 1A-116 binding. Since Cdc42 Rho
GTPase presents a 70% sequence identity with Rac1 and has
differences in key residues such as a phenylalanine in the
56 position, docking experiments were carried out. These
experiments show increased binding energy for 1A-116 docked
to Cdc42 compared to its binding energy to Rac1. This reduction
in binding affinity seems to be due to the loss of the H-bond
established between 1A-116 and the W56 residue of Rac1.
Moreover, we also docked 1A-116 to a Rac1 W56F mutant
and to a Cdc42 F56W mutant showing a striking congruence,
spotlighting W56 as the key residue for 1A-116 binding. The
3D-structure of Rac1 in complex with Tiam1 GEF showed
that W56 generates hydrogen-bond type interactions with the
histidine 1178 of Tiam1, also establishing numerous van der
Waals interactions with nearby amino acids (Gao et al., 2001).
Substitution of W56 by phenylalanine causes a lower occupation
of the hydrophobic pocket of Rac1 (due to the smaller size of
phenylalanine), with the consequent loss of interactions with the
amino acids of the GEF. Collectively, these results prompted
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us to explore the biochemical significance of W56 residue
in vitro.
Using a widely used bioluminescent luciferase reporter system
based on the serum response element (SRE), we explored the
effect of 1A-116 on Rac1 and Cdc42 GTPases activities. Of
note, SRE reporter system is regulated by different members
of Rho GTPase family of proteins and presents interesting
features such as sensitivity, wide dynamic range and lack of
endogenous activity that makes it a good reporter system
to evaluate the in vitro activity of 1A-116 (Montaner et al.,
1999). 1A-116 effectively inhibited Rac1 activity and did not
affect Cdc42-mediated SRE activation in vitro, results that were
previously shown using pull down assays (Cardama et al., 2014a).
These SRE-Luc experiments were carried out using the Q61L
mutant of Rac1 in order to increase the sensitivity of the
reporter system. Eventhough this mutant version is associated
to a constitutive activity, it retains GEF and/or GAP mediated
regulation. This has already been shown in mutant versions of
other GTPases, such as Ras oncoprotein, where the mutation
causes the loss of interaction with GAP proteins. Additionally, it
has been recently demonstrated that novel compounds designed
block the G12C K-Ras mutant surprisingly exhibit certain
dependency to nucleotide exchange promoted by GEF activity
(Ostrem et al., 2013).
Additionally, Rac1 W56F and Cdc42 F56W mutants
developed by site-directed mutagenesis showed a close
dependency of W56 presence in Rac1-GEF binding pocket.
Taking into account these results, we postulate that 1A-116
prevents the correct positioning of the GEF, inhibiting the
activation of Rac1. These experimental data shows a correlation
between in silico and in vitro testing, pointing out to the crucial
role of W56 on 1A-116 binding and activity.
Recently, two independent whole-exome sequencing studies
revealed a novel gain-of-function mutation of Rac1 in sun-
exposed melanomas, being the most frequently observed somatic
mutation after BRAF and NRAS mutations (Hodis et al., 2012;
Krauthammer et al., 2012). Of interest, Rac1 P29S mutant has
been identified as an essential growth driver that promotes cell
proliferation, confers resistance to BRAF inhibitors and may
be involved in immune escape by enhancing PD-L1 expression
(Watson et al., 2014; Vu et al., 2015). We evaluated 1A-116
binding to Rac1 P29S mutant in silico and using the SRE-
luciferase reporter system. In both cases, 1A-116 was able to
inhibit Rac1 P29S activation, showing the potentiality to use 1A-
116 compound in Rac1 P29S-driven tumors (Davis et al., 2013).
Further studies are required to determine the therapeutic efficacy,
but it may represent an interesting precision medicine strategy for
melanoma treatment.
Although the presence of the Rac1 mutation in melanoma,
it is more often that tumors show altered expression and/or
mutations in upstream regulatory proteins, such as GEFs (Vigil
et al., 2010). It has been shown that different groups of GEFs
are relevant in different tumor types; therefore, we evaluated
the effect of 1A-116 on SRE activation by a group of different
constitutively active GEFs. We tested the activity of the members
of the Vav family (Vav1, Vav2, and Vav3), Tiam1 and DBL and
1A-116 was able to block the activity of all these activators in the
SRE-luc reporter assay. Vav family of GEFs are required for the
development of breast cancer, leukemia and skin cancer (Chang
et al., 2012; Citterio et al., 2012; Menacho-Márquez et al., 2013),
while Tiam1 overexpression correlates with tumor progression in
pancreatic cancer, breast cancer and colorectal cancer (Li et al.,
2016; Ding et al., 2018; Izumi et al., 2019).
Rac1 has previously been shown to be involved in the
defective activation of several signaling cascades leading to
anomalous behavior of cells and ultimately contributing to
cancer progression. Moreover, Rac1 is involved in epithelial-
mesenchymal transition (EMT), a key process in the metastatic
cascade (Lv et al., 2013; Nakaya et al., 2004). Metastasis is the end
of a very complex multistep process where cancer cells migrate
from their primary site and colonize other organs. It accounts
for 90% of cancer deaths (Lyden et al., 2011). Rho GTPases
have an essential role during the metastatic cascade. Rac1, in
particular, contributes to cancer development, stimulating cell
proliferation and loss of cell polarity (Ellenbroek and Collard,
2007) and by altering cell-to-cell and cell-to-matrix junctions, it
promotes migration and invasion to distant sites.
Rac1 also regulates cytoskeleton reorganization, and promotes
the formation of cell surface extensions like lamellipodia,
a classical feature of mesenchymal movements (Parri and
Chiarugi, 2010). The invasive phenotype of metastatic cancer
cells causes the remodelation of extracellular matrix by producing
metalloproteases, key components of the EMT also regulated by
Rac1 (Ellenbroek and Collard, 2007; Bosco et al., 2009).
The central role of the Rac1 pathway in the metastatic
phenotype was well demonstrated by different studies. It has
been shown a direct relationship between Rac1 activation and
the metastatic potential of breast cancer cells (Baugher et al.,
2005). Moreover, Rac1 activity and increased levels of PAK1
expression were associated with lymph nodes metastasis in
urothelial carcinoma (Kamai et al., 2010). Finally, GEFs like
VAV2 showed to be important in squamous carcinomas of the
head and neck (Patel et al., 2007) and VAV3 in glioblastoma and
breast cancer (Chan et al., 2005). Depletion or inhibition of these
GEFs impaired cell migration, invasion and proliferation.
Using different cancer models, we have already validated
Rac1 as a target and 1A-116 as a small molecule to be
potentially exploited in therapeutics schemes (Cardama et al.,
2014a; Cabrera et al., 2017; Gonzalez et al., 2017). Of
interest, Rac1 has been shown to have a vital role in skin
physiology (Benitah et al., 2005; Castilho et al., 2010) and
Rac1 hyperactivation drives pathologic conditions, promoting
proliferation of keratinocytes and immune infiltrate (Chen
et al., 2014). Indeed, Rac1 showed a hyperproliferative-specific
function in a genetically engineered keratinocyte restricted Rac1
deletion mouse model (Wang et al., 2010), and Rac1 expression
was found to be elevated in papillomas and squamous cell
carcinomas (Benitah et al., 2005). We showed here that 1A-
116 could inhibit keratinocytes hyperplasia, reducing invasive
phenotype and tissue disorganization. This hyperplastic 3D
model was established by stably transfecting human Ker-CT cells
with different members of Rac1 pathway. In all the cases, the
organotypic 3D keratinocyte culture showed a hyperproliferative
phenotype compared to the control cells but only GEF-driven
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(Vav2) and Rac1-driven hyperplasia were reversed by 1A-
116 treatment.
Additionally, we performed pull down assays showing that 1A-
116 interferes with Rac1 activation. Collectively, these results are
consistent with the initial rational design of 1A-116 as a GEF-
Rac1 PPI inhibitor and show that 1A-116 is able to reduce Rac1
signaling pathway at the nanomolar range of concentration in
a 3D skin model. Nevertheless, these results do not discard the
possibility that 1A-116 interaction with W56 residue could affect
Rac1 affinity to some effectors such as PLC-γ2 (Jezyk et al., 2006;
Bunney et al., 2009) and contribute to 1A-116 effect. However,
1A-116 has no effect whatsoever on PAK1 activity, as shown
throughout our work. Rac1 has been historically linked to actin
dynamics regulation, and 1A-116 can interfere with this activity.
In this regard, we also showed that 1A-116 negatively affects the
formation of different actin-based structures such as membrane
ruffles and lamellipodia. These results show that 1A-116 is able to
modulate Rac1-mediated processes such as actin dynamics and
keratinocyte hyperproliferation.
As we mentioned above, the Rac1 pathway, including both
upstream activators and downstream effectors, is a critical
player in the invasive and metastatic phenotype. This has been
shown in a great variety of tumor types and gives the basis to
consider Rac1 as an attractive and validated target to develop
molecular therapies against cancer metastasis. Therefore, our
results support a critical role of W56 residue of Rac1 in 1A-116
activity. We validated by in silico and in vitro approaches that
1A-116 is only able to exert its activity when W56 is present
in the protein structure. Further, 1A-116 showed its ability to
interfere in different Rac1-mediated biological processes under
different experimental settings, including a hyperproliferative 3D
keratinocyte model. Importantly, 1A-116 is able to interfere with
Rac1 P29S mutant activity, and this may provide an interesting
therapeutic strategy for melanoma patients with a particular
mutation profile. Taken together, we can conclude that 1A-116
is a PPI inhibitor able to selectively bind to W56 residue in
Rac1 protein structure and may represent a suitable therapeutic
agent for different types of neoplasms as well as pre-malignant
disorders involving hyperproliferative phenotypes.
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